Founded in 2000 and based in Tallassee, Alabama, TriLogic Pharma specializes in developing and marketing innovative drug delivery platforms for both human and animal health. The company's core mission is to enhance therapeutic outcomes by overcoming the limitations of traditional systemic and oral antibiotic therapies, such as joint pain and gastric discomfort. TriLogic Pharma's flagship product is an in-situ gel that provides localized treatment, improving patient compliance and tolerability.
TriLogic Pharma has made significant strides in the pharmaceutical industry with its advanced hydrogel technology, which features in-situ gelation and bioresorption with adhesion. The company has garnered attention from notable investors and industry experts due to its groundbreaking approach to drug delivery. TriLogic Pharma's impact is evident in its contribution to better therapeutic compliance and overall patient well-being, setting new standards in both human and veterinary medicine.
